The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. We ...
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...
1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. ...
Click to read this study in JAMA Network Open.
1. Fewer patients in the hyperfractionation group reported grade 3 or worse late radiation-induced complications compared to the standard fractionation ...
Click to read this study in JAMA Surgery.
Click to read this study in JAMA Network Open.
Click to read this study in JAMA Oncology.
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
